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Abstract
Background: HIV-associated tuberculosis is a common coinfection in Sub-Saharan Africa, which causes high morbidity and
mortality. A sub-set of HIV-associated tuberculosis patients require prolonged hospital admission, during which
antiretroviral therapy initiation may be required. The aim of this study was to document the causes of clinical deterioration
of hospitalised patients with HIV-associated tuberculosis starting antiretroviral therapy in order to inform healthcare
practice in low- to middle-income countries.
Methods: Prospective, observational cohort study of adult inpatients with HIV-associated tuberculosis starting antiretroviral
therapy in a dedicated tuberculosis hospital in Cape Town, South Africa. Causes of clinical deterioration and outcome were
recorded in the first 12 weeks of antiretroviral therapy. Patients with rifampicin-resistant tuberculosis were excluded.
Results: Between May 2009 and November 2010, 112 patients (60% female), with a median age of 32 years were enrolled. At
baseline the median CD4 count was 55 cells/mm3 (IQR 31–106) and HIV viral load 5.6 log copies/mL. All patients had
significant comorbidity: 82% were bed-bound, 65% had disseminated tuberculosis and 27% had central nervous system
tuberculosis. Seventy six patients (68%) developed 144 clinical events after starting antiretroviral therapy. TB-IRIS, hospital-
acquired infections and significant drug toxicities occurred in 42%, 20.5% and 15% of patients respectively. A new
opportunistic disease occurred in 15% of patients and a thromboembolic event in 8%. Mortality during the 12 week period
was 10.6%.
Conclusions: High rates of TB-IRIS, hospital-acquired infections and drug toxicities complicate the course of patients with
HIV-associated tuberculosis starting antiretroviral therapy in hospital. Despite the high morbidity, mortality was relatively
low. Careful clinical management and adequate resources are needed in hospitalised HIV-TB patients in the 1st three months
following ART initiation.
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Introduction
The World Health Organisation estimates that over 80% of all
cases of HIV-associated tuberculosis (HIV-TB) occur in Africa. [1]
HIV-TB causes significant morbidity with high case fatality rates
during treatment (18.8%, 95% CI: 14.8–22.8%) [2], especially in
patients with advanced immunodeficiency. Many of the deaths
occur early after tuberculosis diagnosis. [3] Concomitant anti-
retroviral therapy (ART) reduces mortality in patients with HIV-
TB [3] and, in patients with very advanced immunosuppression
(CD4,50 cells/mm3), outcomes are best if ART is started ,2
weeks after commencing tuberculosis treatment.[4–6] Paradoxical
tuberculosis-immune reconstitution inflammatory syndrome (TB-
IRIS) and significant drug toxicity are common complications in
patients who start ART soon after tuberculosis treatment.[4–6]
Other potential causes for clinical deterioration in this group
include complications due to tuberculosis (e.g. haemoptysis,
pneumothorax), new opportunistic diseases, drug resistant tuber-
culosis, bacterial infections, venous thromboembolism and drug-
drug interactions.[7–9].
HIV-TB patients with severe immunocompromise commonly
have disseminated tuberculosis and significant comorbidity, and
often require admission to longterm care facilities or dedicated
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tuberculosis hospitals. In Sub-Saharan Africa the majority of ART
programs are outpatient-based requiring regular clinic attendance
prior to starting ART. Few patients start ART in hospital, and
studies that report the complications and outcomes among
inpatients starting ART are limited. We aimed to describe the
causes for clinical deterioration in hospitalised HIV-TB patients
starting ART in order to inform resource allocation of diagnostic
and therapeutic services required at tuberculosis hospitals in low-
and middle-income countries.
Methods
Design and Setting
A prospective, observational cohort study of hospitalised
patients with HIV-TB was conducted at Brooklyn Chest Hospital
(BCH) from 29 April 2009 until 28 February 2011. BCH is
a district level tuberculosis hospital serving the Cape Town
metropole. Inpatients at BCH are either too ill for ambulatory care
or have drug-resistant TB, and are transferred in from hospitals or
TB clinics with a diagnosis of tuberculosis already made and TB
treatment initiated. The adult inpatient population has been
previously described; where more than two-thirds of patients in the
drug-sensitive wards are HIV-co-infected, of whom 98% had
significant comorbidities and 60% had a Karnofsky performance
score of #30. [10] An integrated ART program was started at
BCH in 2008.
Study Population and Eligibility
Eligible patients were adults ($18 years), hospitalised at BCH
with confirmed HIV infection and a diagnosis of pulmonary (PTB)
or extrapulmonary tuberculosis (EPTB), not on ART, who fulfilled
national criteria for starting ART at the time of the study; CD4
count ,200 cells/mm3 or WHO Stage 4 defining illness until 31
March 2010, following which guidelines changed to include all
patients with HIV-TB and CD4 count #350 cells/mm3.
Exclusion criteria included patients with known rifampicin-re-
sistant tuberculosis and those unable to provide informed consent.
First episodes of tuberculosis were treated as per national policy
with standard fixed dose combination tablets composed of
rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol
(E) for the 2-month intensive phase followed by RH for the 4-
month continuation phase. For retreatment tuberculosis, RHZE
was given for 3 months with 40-doses of streptomycin followed by
RHE for 5 months. Prior to 1st April 2010, first-line ART
comprised stavudine (d4T), lamivudine (3TC) and efavirenz as the
preferred non-nucleoside reverse transcriptase inhibitor (NNRTI)
in patients on concurrent TB therapy. In April 2010 new national
guidelines were introduced with tenofovir (TdF) replacing d4T.
Unless contraindicated, all patients received cotrimoxazole
960 mg daily as prophylaxis, and pyridoxine 25–50 mg daily
during tuberculosis treatment as well as subcutaneous unfractio-
nated heparin (5000 IU subcutaneously 12 hrly) for deep vein
thrombosis prophylaxis if bedbound.
Study Procedure
Follow-up was for 12 weeks after starting ART. Patients were
assessed at 8 time-points: enrolment, ART initiation, then weekly
for four weeks and again at week 8 and week 12 after ART
initiation. At each scheduled visit, an infectious diseases specialist
examined patients and targeted laboratory (including bacterial
cultures and serum cryptococcal antigen) and radiological
investigations were performed if there was clinical deterioration.
Baseline clinical and laboratory data was recorded: age, gender,
CD4 T-lymphocyte count (CD4 count), HIV viral load, WHO
stage, comorbid condition(s), weight and ambulatory status.
Reasons for not being on ART at admission and prior ART
exposure was established. Tuberculosis data included: prior
tuberculosis episode(s), site of tuberculosis (EPTB/PTB), diagnos-
tic method (smear, culture, clinical), and TB drug details
(susceptibility, regimen, duration, serious adverse drug reactions
prior to starting ART). Unscheduled visits and additional
investigations occurred in the event of clinical deterioration.
Routine care was the responsibility of the ward doctor and nursing
staff.
We recorded the following outcome measures in the event of
a clinical deterioration: new WHO stage 4 defining condition,
drug-induced toxicity requiring a drug switch, hospital acquired
infection, TB-IRIS, and significant other comorbidity necessitating
investigation and treatment.
Definitions
Tuberculosis was diagnosed on the basis of smear or culture
positivity. Where this was negative or unavailable, diagnosis was in
line with WHO guidelines for diagnosis of smear negative or
extrapulmonary tuberculosis in HIV-1 infected persons. [11] TB-
IRIS was diagnosed according to the International Network for
the Study of HIV-associated IRIS (INSHI) case definitions. [12]
Hospital acquired infection (HAI) was defined as an infection
acquired after 48 hours of hospital admission that was not
clinically apparent at the time of the patient’s hospital admission.
When organisms were cultured in the absence of an inflammatory
response, the isolate was regarded as a colonising microorganism,
and not classified as a HAI. [13].
Ethics
The study was approved by the University of Cape Town’s
Faculty of Health Sciences Research Ethics Committee (HREC
No: 049/2009) and the Provincial Research Committee of the
Department of Health, Western Cape. All participants signed
written informed consent.
Statistical Analysis
Data were analysed using Stata version 12.0 (Stata Corporation,
USA). Measures were described with medians and interquartile
ranges (IQR) or proportions. We used chi-square tests (replaced by
exact tests for sparse data) to compare proportions, rank-sum tests
to compare medians, and t-tests to compare mean values between
groups. Kaplan-Meier methods were used to describe the survival
of patients over time.
Results
Patient Characteristics
A total of 130 participants were screened for enrollment
(figure 1), 112 of whom met inclusion criteria and started ART in
hospital. Baseline characteristics are shown in table 1. The cohort
was characterised by advanced immunosuppression with WHO
stage 4 disease in the majority, very low median CD4 cell count,
high baseline HIV viral load and 81% were bed-bound.
Approximately two thirds had disseminated tuberculosis and only
a minority, 17% and 18% respectively, had exclusively pulmonary
or extrapulmonary TB at a single site. Just over half of patients
were presenting with a repeat episode of tuberculosis and 50%
were newly diagnosed with HIV.
The median time from the start of anti-tuberculosis treatment to
ART start was 36 days (IQR, 27–57) and the majority (95%)
received an efavirenz-based regimen, more commonly with
tenofovir than stavudine (Table 2). Twenty-four patients (21%)
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were receiving corticosteroids at the time of starting ART; the
main indication for using corticosteroids was for TB meningitis in
20 patients. Ninety-six patients completed 12-weeks of follow-up,
with 4 patients absconding from hospital after completing 8 weeks
of inpatient ART.
Figure 1. Patient enrollment. LTFU = lost to follow-up, TFO = transferred out.
doi:10.1371/journal.pone.0054145.g001
Table 1. Baseline Characteristics of 112 HIV-TB Inpatients
starting ART.
Age: years, median (IQR) 32 (27–40)
Female gender, n (%) 67 (60)
CD4 count, cells/mm3, median, (IQR) 55 (31–106)
HIV viral load, log copies/mL, median (IQR) 5.6 (5.1–6.1)
WHO Stage 4, n (%) 97 (87)
Haemoglobin, g/dL, median (IQR) 9.0 (8.7– 10.3)
Weight, kg, median (IQR) 46 (39–52)
Bed bound: n (%) 91 (82)
Corticosteroids at baseline: n (%) 25 (22)
Tuberculosis
Diagnosis microbiologically confirmed: n (%)* 86 (77)
Previous TB: n (%) 66 (59)
Exclusively PTB: n (%) 19 (17)
EPTB at single site: n (%) 20 (18)
Disseminated TB: n (%) 73 (65)
Neurological TB: n (%) 30 (27)
*82 cultured MTB, and 4 only smear positive.
doi:10.1371/journal.pone.0054145.t001
Table 2. Antiretroviral therapy and duration of
hospitalization.
Reason not on ART at enrollment
New HIV diagnosis: n (%) 57 (51)
Did not fulfill criteria for ART previously 1, n (%) 13 (12)
Personal reasons e.g. denial, n (%) 11 (10)
ART
ART naı¨ve, n (%) 109 (97)
Median time from starting TB treatment to ART start,
days (IQR)
36 (27–57)
Median time from hospitalization to ART start,
days (IQR)
16(12–23)
ART regimen, n (%)
D4T 3TC EFV 43 (38)
TdF 3TC EFV 54 (48)
AZT 3TC EFV 10 (9)
D4T 3TC NVP 4 (4)
AZT, 3TC, lopinavir/ritonavir 1 (1)
Hospital stay
Duration of admission at referral hospital, days,
median (IQR)
15 (11–31)
Length of admission at BCH* 99 (75–130)
1CD4.200 cells/mm3, WHO clinical stage 1–3.
*Information available for 94 subjects only, deaths excluded.
doi:10.1371/journal.pone.0054145.t002
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Clinical Deterioration
Overall 76 (68%) patients experienced a significant clinical
deterioration after initiating ART. A total number of 144 events
were recorded with a median of 2 events (range 1–5) per patient.
Paradoxical TB-IRIS, HAI, drug toxicity (most commonly
efavirenz-related neuropsychiatric toxicity) and unmasking of
opportunistic diseases (most commonly oesophageal candidiasis,
Pneumocystis jirovecii pneumonia and Kaposi’s sarcoma) were the
main reasons for deterioration (Table 3).
Paradoxical TB-IRIS occurred in 42% of patients. The median
duration from starting ART to the onset of TB-IRIS symptoms
was 12 days (range 4–49 days). Seven patients developed
potentially life-threatening IRIS, 6 due to worsening tuberculous
meningitis and one due cardiac tamponade requiring urgent
pericardiocentesis. The only baseline variable that was significant-
ly associated with the development of TB-IRIS on univariate
analysis was CRP.10 mg/L (Hazard ratio; 95% confidence
interval: 1.7 [1.1–2.6]). Corticosteroid use at the time of ART
initiation was associated with a 40% reduction in TB–IRIS
incidence, however this was not statistically significant (p = 0.06).
Twenty-three patients (20.5%) developed an HAI, the com-
monest being urinary tract sepsis in 9 patients. Seven patients had
sepsis syndrome with a bloodstream infection, 3 pneumonia, 3
Clostridium difficile diarrhoea and one patient developed chickenpox
acquired following an exposure to another patient with herpes
zoster. Thirteen isolates were identified in the 22 patients with
bacterial sepsis, 9 of which were multi-drug resistant bacteria: 8
extended spectrum b-lactamase (ESBL)-producing enterobacter-
iaceae (7 from urine culture and 1 blood culture) and 1 methicillin-
resistant Staphylococcus aureus (sputum culture).
Mortality
Twelve patients died during the 12-week follow-up period
resulting in cumulative mortality of 10.6% (Figure 2). Neurological
tuberculosis, weight ,50 kg, corticosteroid use at time of ART
initiation, being bed-bound, or CD4 cell count ,50 cells/mm3
were not significantly associated with mortality. The cause of
death was ascribed to sepsis in 11 patients and pulmonary
embolism in one. None of the deaths were thought to be directly
caused by paradoxical TB-IRIS.
Discussion
Our study demonstrated that over two-thirds of hospitalised
HIV-TB patients develop complications resulting in clinical
deterioration after starting ART as inpatients. Over 40%
experienced paradoxical TB-IRIS, with HAIs, drug toxicities,
and opportunistic diseases being other frequent causes of de-
terioration. A novel finding is that HAIs were common (occurred
in 20.5%), and 11 of the 12 deaths were attributed to sepsis.
Reassuringly, despite the high incidence of clinical deterioration,
89% of participants were alive three months after ART initiation.
Adequate clinical care and diagnostic and therapeutic resources
are required to manage this HIV- as well as tuberculosis-associated
morbidity.
HIV infection, especially with a low CD4 count, is a risk factor
for clinical deterioration and death on TB treatment. [9] A
previous study conducted in Cape Town of 292 ambulatory TB
patients, 209 of whom were HIV-infected, demonstrated that 40%
deteriorated while on TB therapy, 26% required hospitalization,
and 15% died during the 6 month follow-up period. [9] Training
health care workers on the causes, recognition and management of
deterioration in HIV-TB patients, in addition to training on ART
management, is required to optimize the outcome of HIV-TB
patients.
The high incidence of paradoxical TB-IRIS in our study (42%)
corresponds with the higher estimates reported from previous
cohort studies (8–43%) [14]. Our patients had many of the risk
factors for developing TB-IRIS; low CD4 counts, disseminated
tuberculosis and relatively short time interval between starting
tuberculosis therapy and ART. Our findings add to the evidence
that paradoxical TB-IRIS is an uncommon cause of mortality
[15], even in very ill HIV-TB patients starting ART in hospital.
One caveat is that 7 of 47 IRIS cases developed potentially life-
threatening manifestations and these were promptly ascertained
and managed by specialists with early corticosteroid introduction
or dose escalation. The association of a raised CRP prior to
starting ART with paradoxical TB-IRIS has been previously
described. [16] Being on corticosteroids at the time of initiating
ART showed a trend towards reduced risk for TB-IRIS, although
this was not statistically significant in this small study. Larger
prospective studies would be necessary to evaluate this properly.
The large number of HAIs we diagnosed, and the associated
mortality is alarming. Our findings suggest that once patients with
advanced HIV and TB are established on appropriate TB
treatment, ART and cotrimoxazole, then bacterial infections
emerge as the most important cause of death. We suspect that
colonization with multi-drug resistant bacteria occurred in the
referring general hospital, as antibiotic selection pressure in TB
hospitals is likely to be low. High rates of urinary catheterization
during the acute admission at the referring hospital, is a likely
contributing risk factor to the urinary tract infections. Depressed
monocyte responses may be one of the reasons why HIV-infected
patients with advanced immunosuppression are at high risk of
bacterial infections. [17] Our study and a previous study from
a hospitalized cohort in Cape Town [8], confirm that drug-
resistant bacteria which require the use of carbapenems and other
costly antibiotics are causing HAI. These antibiotics are generally
unavailable at district or secondary level hospitals in developing
countries and there is therefore often a delay in treating these
infections appropriately resulting in high mortality. Furthermore,
because the risk of multi-drug resistance is high in HAIs, it is
essential to culture clinical specimens prior to commencement of
antibiotics. Our findings emphasize not only the need for
appropriate antibiotics to be available, but for basic infection
prevention control practices, most importantly effective hand
disinfection, to be re-inforced and practiced to prevent secondary
spread of infection. Reducing the number of days that patients
have urinary catheters in situ, and wherever possible avoiding the
need for indwelling intravenous catheters are also important
Table 3. Causes of clinical deterioration.
Cause n (%)
Tuberculosis – IRIS 47 (42)
Drug Toxicity 23 (20.5)
Hospital acquired infection 23 (20.5)
Opportunistic disease (includes Kaposi’s sarcoma) 17 (15)
Deep vein thrombosis or pulmonary embolism 9 (8)
Herpes virus reactivation 8 (7)
Other 17 (15)
*Patients commonly had more that one episode of clinical deterioration, in total
144 episodes of deterioration were recorded.
n = 144*.
doi:10.1371/journal.pone.0054145.t003
Complexity of ART in Hospitalised HIV-TB Patients
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e54145
interventions. Every attempt is made to limit duration of hospital
stay. However, severity of illness and extremely poor social
circumstances often preclude early discharge.
Our study has several limitations. The follow-up period was
limited to the first 3 months of ART, so events occurring in the
latter half of TB therapy were not ascertained. The generalizability
of our findings is limited by the fact that all participants in the
study were evaluated by a specialist physician trained in infectious
diseases at study visits, which could in part explain our relatively
low mortality. There was no control group to ascertain outcome of
patients who did not receive input from an Infectious Diseases
specialist. Another factor limiting generalizability of our outcomes
is that BCH is relatively well-resourced with access to radiology
and laboratory services. It is unlikely that such good outcomes can
be achieved in less well-resourced facilities, which would be found
in the majority of TB hospitals in low- to middle-income countries.
However, specialist input and access to diagnostic facilities allowed
us to ascertain the frequency and type of complications occurring
in sick HIV-TB inpatients starting ART. Another limitation is that
not all patients developing sepsis had appropriate cultures sent, as
transportation of specimens to the off-site microbiology laboratory
occurs only once a day during weekdays. In addition the causes of
death were ascertained by the attending infectious diseases
specialist and no post-mortem studies were performed on the
patients. For the analysis of predictors of mortality the sample size
was to too small to allow for meaningful comparison between
groups.
Our findings have important implications for service delivery
and resource allocation at hospitals offering dedicated tuberculosis
services. HIV-TB patients requiring long term admission are
a vulnerable group with advanced immunosuppression, frequently
have disseminated tuberculosis, and are at high risk of early
mortality if ART is not initiated timeously. Three landmark trials
have shown that ART initiated within 2–3 weeks after starting TB
therapy in patients with HIV-associated tuberculosis and
a CD4,50 cells/mm3 results in a reduction in death and
AIDS.[4–6] Where HIV-TB services are not integrated, hospital-
ized HIV-TB patients are referred to primary community ART
clinics after discharge, resulting in unnecessary delay of ART
initiation and this likely increases mortality. If HIV-TB patients
have to attend outpatient ART clinics to initiate ART during their
hospital stay, there is a risk of transmitting M. tuberculosis, including
drug-resistant strains to the HIV-infected clinic population.
Hence, integrating ART initiation into tuberculosis hospitals is
vital to expedite ART initiation as well as to prevent TB
transmission in ART clinics. With proper human resource
allocation to tuberculosis hospitals such as BCH, ‘fast-track’
counselling can be employed to ensure patients are treatment
ready. Patients in our study started ART a median of 36 days after
TB treatment, much of the delay occurring because of the period it
took for patients to be admitted to BCH after TB diagnosis.
The strength of our study is that it illustrates the clinical
complexity of starting ART in hospitalized HIV-TB inpatients and
the need for clinicians trained in the clinical management of these
very ill patients. It argues strongly for proper training and resource
allocation to manage this vulnerable group of patients.
Conclusions
High rates of paradoxical TB-IRIS, HAIs, drug toxicities and
new opportunistic infections occur in hospitalised HIV-TB
inpatients with advanced immunosuppression initiating ART.
Despite the high morbidity, relatively good short-term outcomes
can be achieved with careful clinical management. There is a need
for prospective studies in other settings, and for additional studies
evaluating the effect of training and the provision of ART to HIV-
TB inpatients.
Figure 2. Kaplan-Meier curve showing survival of 112 patients with HIV-TB, from the start of antiretroviral therapy.
doi:10.1371/journal.pone.0054145.g002
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